Citations 64

P3–194: Age‐specific incidence rates of Alzheimer's disease in family members participating in the NIA‐LOAD genetics study

Alzheimer's & Dementia | October 9, 2013 | Volume: 9 | Issue: 4S_Part_15 | Pages: No page available

10.1016/j.jalz.2013.05.1266

P1–063: Association of TREM2 variants with Alzheimer's disease in African‐Americans: For the Alzheimer's Disease Genetics Consortium (ADGC)

Alzheimer's & Dementia | October 9, 2013 | Volume: 9 | Issue: 4S_Part_4 | Pages: No page available

10.1016/j.jalz.2013.05.284

O2–03–01: Validation of the Alzheimer's Prevention Initiative Composite Cognitive Test Score

Alzheimer's & Dementia | October 9, 2013 | Volume: 9 | Issue: 4S_Part_8 | Pages: No page available

10.1016/j.jalz.2013.04.147

GWAS of 126,559 Individuals Identifies Genetic Variants Associated with Educational Attainment

Science | May 31, 2013 | Volume: 340 | Issue: 6139 | Pages: 1467-1471

10.1126/science.1235488 | PMID 23722424

Genetic College Many genomic elements in humans are associated with behavior, including educational attainment. In a genome-wide association study including more than 100,000 samples, Rietveld et al. (p. 1467 , published online 30 May; see the Perspective by Flint and Munafò ) looked for genes related to educational attainment in Caucasians. Small genetic effects at three loci appeared to impact educational attainment.
P4‐126: Genome‐wide exploration of DNA methylation in the aging brain and its relation to Alzheimer's disease

Alzheimer's & Dementia | July 19, 2012 | Volume: 8 | Issue: 4S_Part_18 | Pages: No page available

10.1016/j.jalz.2012.05.1829

O1‐09‐01: CTNNA3, CAPRIN2 and SPG20 are significantly associated with Alzheimer's disease in preliminary analyses of a genome‐wide association study in African‐Americans

Alzheimer's & Dementia | July 19, 2012 | Volume: 8 | Issue: 4S_Part_3 | Pages: No page available

10.1016/j.jalz.2012.05.251

Genotype patterns atPICALM, CR1, BIN1, CLU, andAPOEgenes are associated with episodic memory

Neurology | April 27, 2012 | Volume: 78 | Issue: 19 | Pages: 1464-1471

10.1212/wnl.0b013e3182553c48 | PMID 22539578

O3‐03‐02: Composite cognitive endpoints with improved power to detect presymptomatic Alzheimer's disease treatment effects in APOE4 carriers: Findings from the Alzheimer's prevention initiative

Alzheimer's & Dementia | August 1, 2011 | Volume: 7 | Issue: 4S_Part_14 | Pages: No page available

10.1016/j.jalz.2011.05.2401

P1‐281: Multilocus genotype pattern at PICALM, CLU and APOE genes is associated with episodic memory in the NIA‐LOAD/NCRAD study

Alzheimer's & Dementia | August 1, 2011 | Volume: 7 | Issue: 4S_Part_6 | Pages: No page available

10.1016/j.jalz.2011.05.562

Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Alzheimer's & Dementia | April 22, 2011 | Volume: 7 | Issue: 3 | Pages: 280-292

10.1016/j.jalz.2011.03.003 | PMID 21514248

The pathophysiological process of Alzheimer's disease (AD) is thought to begin many years before the diagnosis of AD dementia. This long “preclinical” phase of AD would provide a critical opportunity for therapeutic intervention; however, we need to further elucidate the link between the pathological cascade of AD and the emergence of clinical symptoms. The National Institute on Aging and the Alzheimer's Association convened an international workgroup to review the biomarker, epidemiological, and neuropsychological evidence, and to develop recommendations to determine the factors which best predict the risk of progression from “normal” cognition to mild cognitive impairment and AD dementia. We propose a conceptual framework and operational research criteria, based on the prevailing scientific evidence to date, to test and refine these models with longitudinal clinical research studies. These recommendations are solely intended for research purposes and do not have any clinical implications at this time. It is hoped that these recommendations will provide a common rubric to advance the study of preclinical AD, and ultimately, aid the field in moving toward earlier intervention at a stage of AD when some disease‐modifying therapies may be most efficacious.